MicroRNA-373 promotes cell migration via targeting salt-inducible kinase 1 expression in melanoma

XINPING BAI¹, MING YANG¹ and YI XU²

¹Department of Plastic Surgery, Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430014; ²Department of Plastic Surgery, The Third People’s Hospital of Hubei Province, Wuhan, Hubei 430033, P.R. China

Received May 10, 2017; Accepted September 13, 2017

DOI: 10.3892/etm.2018.6784

Abstract. It is well established that altered expression of microRNAs (miRs) is critical in numerous human cancer types. Nevertheless, the molecular mechanisms of many miRs are yet to be elucidated. In the present study, reverse transcription-quantitative polymerase chain reaction and western blot analyses, and cell migration assays were performed to verify dysregulation of miR-373 in melanoma and its biological function. The transcriptional level of miR-373 was identified to be upregulated in melanoma tissues and cell lines compared with nevus and normal melanocytes. miR-373 was identified to function as an oncomiR, promoting melanoma cell migration. Notably, miR-373 was observed to suppress its downstream gene salt-inducible kinase 1 (SIK1) through directly binding the 3'-untranslated region of SIK1 expression. Furthermore, reduced SIK1 expression was identified to be responsible for the oncogenic effect of miR-373. In conclusion, the present study indicates that miR-373 functions as an oncomiR to promote melanoma progression through targeting SIK1 expression. This may provide a new therapeutic approach for melanoma.

Introduction

The past decade has seen a rapid increase in the incidence in melanoma, it is estimated that the annual increase in the incidence rate of melanoma has been ~3-7% per year worldwide for Caucasians (1). Melanoma is one of the most lethal of all adult malignancies due to its extremely high tendency to metastasize towards multiple human organs, such as the liver, brain and lung (2,3). The median survival following the onset of distant metastases is 6-9 months, and the 5-year survival rate is >5% (2,3). Surgery resection remains the primary curative treatment for melanoma at early stages (4). However, treatment of melanoma at late stages is difficult and less effective (5). Therefore, the development of new molecular targeted therapies for melanoma is urgently required.

MicroRNAs (miRs) are small non-coding RNAs (22-26 nucleotides), which inhibit the expression of target genes primarily by binding to the 3'-untranslated region (3'-UTR) of mature mRNAs, leading to mRNA degradation or inhibition of translation (6,7). Aberrant expression of miRs has been reported in various human cancer types. miRs have been reported to function as onco genes or tumor suppressor genes in tumor progression as well as development, encompassing apoptosis, proliferation, migration, invasion, metastasis and resistance to therapy (7-10). Notably, numerous miRs serve pivotal roles in melanoma development and progression (11-13). miR-373 is among the most commonly upregulated miRs in melanoma (14). However, the detailed mechanism of miR-373 in melanoma is yet to be elucidated.

The serine/threonine kinase salt-inducible kinase 1 (SIK1) is a member of the SIK family, which consists of SIK1, SIK2 and SIK3 (15). SIK1 has been reported to be involved in multiple biological processes, including regulation of PKA activity (16) and p53-dependent anoikis through the use of a kinome-wide loss-of-function screen (17). Attenuated SIK1 gene expression is identified to promote various human cancer types. In non-small cell lung cancer, downregulation of SIK1 enhances epithelial-mesenchymal transition (EMT) and radioresistance (18). In addition, induced SIK1 expression has been reported to inhibit gastric cancer cell migration (19). However, the functional role of SIK1 in melanoma remains largely unknown.

In this study, to clarify the vital role of miR-373 in human melanoma, reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analyses were used to detect the expression of miR-373 in clinical samples, wound healing assays were used to detect cell migration and Transwell assays were also used to detect cell migration. Based on the results of the current study, miR-373 was demonstrated to serve as an oncomiR in melanoma, by enhancing melanoma cell migration. Furthermore, miR-373 was observed to attenuate SIK1 protein level through directly binding its 3'-UTR.
Notably, it was also identified that downregulation of SIK1 enhanced melanoma cell migration.

**Materials and methods**

**Clinical sample collection.** A total of 16 melanoma tissues and normal skin samples were collected from patients recruited from the Department of Plastic Surgery, Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology (Wuhan, China) between February 2015 and June 2016. The mean age of the recruited patients (10 male and 6 female) were 56.46 years (standard deviation, 2.63 years). The fresh tissues were frozen in liquid nitrogen (-196°C) to protect the protein or RNA from degradation. The use of human tissues was approved by the Ethics Committee of the Central Hospital of Wuhan and all patients provided written, informed consent.

**Cell culture and transfection.** The human melanoma cell lines A375, WM115 and WM75 were purchased from the Shanghai Institute of Biochemistry and Cell Biology (Shanghai, China), and were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% (v/v) fetal bovine serum (FBS; Thermo Fisher Scientific, Inc.). Luciferase reporter plasmids were constructed in the following manner: the luciferase reporter plasmid pmirGLO (Promega, Madison, WI, USA) or pRL-CMV (Promega) was cotransfected into A375 or WM115 cells using Lipofectamine 2000 (GenePharma Co., Ltd.) was stably transfected in A375 or WM115 cells using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer’s protocol. The medium containing the transfection reagents was removed 6 h after transfection and 48 h later the cells were harvested for the following assays. The transfection efficiency and changes in SIK1 expression were determined by western blotting.

The medium containing the transfection reagents was removed 6 h after transfection and 48 h later the cells were harvested for the following assays.

**RT-qPCR**. Total RNA from tissues or cells was extracted using TRizol reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer’s protocol. cDNA was synthesized using a PrimeScript RT reagent kit (Takara Bio, Inc., Otsu, Japan), according to the manufacturer’s protocol. qPCR was performed with a KAPA SYBR FAST qPCR kit (Kapa Biosystems, Inc., Wilmington, MA, USA) using a 7900HT Fast Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.). The initial denaturation step was for 10 sec at 95°C, followed by 40 cycles of denaturation for 5 sec at 95°C, and annealing and extension for 20 sec at 60°C. The expression levels of miRNA were normalized to endogenous small nuclear RNA U6. The 2^ΔΔCT method was used to analyze the expression level relative to the endogenous control (20). The primers used were as follows: miR-373 forward, 5'-ATT TTGTTAATCCGTGAATTTCTG-3' and reverse, 5'-CTA TCGCCCAAACCTAAATAGAT-3'; SIK1 forward, 5'-TGG ACCTCCTGGACCTCCGTG-3' and reverse, 5'-CTCCGGTCT TCTTTAGCTG-3'; U6 forward, 5'-CTCGCTTCGGAGGTTC GCAAC-3' and reverse, 5'-ACGCTTCACGAAATTTGCGT-3'.

**Western blot analysis.** Protein extraction and western blotting analysis were conducted as described previously (21). The cells were incubated with the primary antibodies, including anti-SIK1 (cat. no. ab64428; 1:1,000; Abcam, Cambridge, MA, USA) or anti-GAPDH (cat. no. sc-25778; 1:5,000; Santa Cruz Biotechnology, Inc., Dallas, TX, USA). Then the membranes were then washed and incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG secondary antibody (cat. no. sc-2004; 1:5,000; Santa Cruz Biotechnology, Inc.).

**Vector construction and luciferase reporter assay.** For the luciferase reporter assay, A375 cells were seeded on 24-well plates.
and co-transfected using Lipofectamine 2000 with 100 ng/well firefly luciferase UTR-reporter vector, 2 ng/well Renilla pRLCMV vector (internal control; all Promega Corporation, Madison, WI, USA) and 20 ng/well of miR-373 mimics or miR-NC (Applied Biosystems; Thermo Fisher Scientific, Inc.), following the manufacturer's protocol. In brief, luciferase reporters were constructed through cloning of the 3'-UTR of SIK1 wild-type (wt) as well as SIK1 mutant-type (mut) via a deletion at position 1,905-1,911. The 3'-UTR of SIK1 mRNA containing the wild-type or mutant miR-373 recognition sequences were PCR-amplified and subcloned into the SacI and SalI sites of the pmirGLO vector (Promega Corporation). A375 cells transfected with miR-373 or miR-NC and cultured in 48-well plates were co-transfected with 1.5 µg of firefly luciferase reporter and 0.35 ng Renilla luciferase reporter with Lipofectamine 2000 regent. After 24 h the relative luciferase activity was assessed with the Dual-Luciferase Assay Reporter system (cat. no. E1910; Promega Corporation) and normalized to Renilla luciferase activity.

Statistical analysis. Data are presented as the mean ± standard deviation from at least three independent experiments. All data were analyzed using GraphPad 6.0 statistical software (GraphPad Software, Inc., La Jolla, CA, USA). Differences between two groups were analyzed using two-independent-sample Student's t-test or non-parametric Mann-Whitney U test. Differences between multiple groups were analyzed using one-way analysis of variance with Dunnett's post hoc test. P<0.05 was considered to indicate a statistically significant difference.

Results

miR-373 is upregulated in melanoma tissues and cell lines. To investigate the expression of miR-373 in melanoma, RT-qPCR was performed. The results indicated that the mRNA level of miR-373 was significantly upregulated in melanoma tissues compared with nevus (Fig. 1A). Next, the expression of miR-373 was evaluated in a panel of normal melanocytes and human melanoma cell lines. The results indicated that miR-373 was significantly upregulated in A375, WM115 and WM75 melanoma cell lines compared with normal melanocytes (Fig. 1B). The results indicated that the expression of miR-373 is increased in melanoma tissues and cell lines.

miR-373 promotes melanoma cell migration. To explore the functional role of miR-373 in melanoma progression, melanoma cells [A375 (relatively highest level of miR-373 among the three cell groups from Fig. 1B) and WM115 (relatively lowest level of miR-373 among the three cell groups from Fig. 1B)] were stably transfected with miR-373 mimics. It was confirmed that the expression of miR-373 was upregulated in A375 and WM115 cells following miR-373 mimic transfection compared with cells transfected with miR-NC (Fig. 2A). As indicated in Fig. 2B and C, a wound healing assay demonstrated that transfection with miR-373 mimic significantly enhanced melanoma cell migration in A375 and WM115 cells compared with transfection with miR-NC. The effects of miR-373 on melanoma cell migration were evaluated further using a Transwell assay (Fig. 2D and E). A375 and WM115 cells transfected with miR-373 mimic were observed to have a significantly higher migration capability compared with cells transfected with miR-NC. These results suggested that miR-373 elevates melanoma cell migration.

3'-UTR of SIK1 is the direct target of miR-373. Among the potential candidate targets of miR-373 was SIK1 (Fig. 3A). Fig. 3B indicates that the seed sequence of miR-373 is complementary to the 3'-UTR of SIK1 and is highly conserved among 18 different species. Dual-luciferase reporter assays illustrated that the transient transfection of A375 cells with SIK1 wt 3'-UTR significantly reduced reporter expression when compared with the control vector (Fig. 3C and D). However, the firefly luciferase reporter activity of the SIK1 mut 3'-UTR was not notably affected by miR-373-transfection (Fig. 3D). This result indicated that the 3'-UTR of SIK1 was targeted by miR-373. Furthermore, western blot analysis results demonstrated that overexpression of miR-373 inhibited SIK1 protein level in A375 and WM115 cells (Fig. 3E). These results supported the conclusion that SIK1 is the target gene of miR-373 in melanoma.

sh-SIK1 augments cell migration in melanoma. The functional role of SIK1 in melanoma was evaluated. The effect of sh-SIK1 and sh-NC on SIK1 expression in A375 and WM115 cell lines was observed via western blot analysis. It was confirmed that transfection with sh-SIK1 resulted in decreased SIK1 expression compared with sh-NC in the two cell lines (Fig. 4A). A375 cells and WM115 cells transfected with sh-SIK1 exhibited significantly increased cell migration compared with sh-NC Transfected cells, as demonstrated by wound healing and Transwell assays (Fig. 4B-E). These results indicated that downregulation of SIK1 promotes melanoma cell progression.

Discussion

Accumulating evidence indicates that miR-373 acts as a tumor suppressor or oncogene in numerous human cancer types (22). More specifically, miR-373 targeting CD44 and transforming growth factor-β receptor 2 suppressed tumor migration and invasion in glioma cells (23). In parallel, miR-373 inhibited ovarian cancer cell invasion and metastasis by targeting RAB22A (24). On the other hand, miR-373
was associated with aggressive human mucinous colorectal cancer (25). Upregulated miR-373 promoted cell migration in breast cancer through epigenetic silencing of integrin subunit α-2 (26). miR-373 enhanced EMT transition and metastasis via targeting thioredoxin-interacting protein in breast cancer (27). However, the association between miR-373 and melanoma remains unclear.

In the present study, it was demonstrated that the expression of miR-373 is upregulated in melanoma tissues and certain melanoma cell lines compared with nevus and normal melanocytes, respectively. Functionally, miR-373 mimics significantly enhanced cell migration in wound healing and Transwell assays in A375 and WM115 cell lines. miR-373 was identified to target downstream gene SIK1 through directly binding a complementary sequence. In addition, downregulated SIK1 was indicated to promote migration in A375 and WM115 cell lines. Collectively, these findings suggest that miR-373 serves as an oncomiR to promote melanoma progression and development via targeting SIK1.

Previous studies have illustrated that SIK1 is downregulated in multiple human tumor types. In human hepatocellular carcinoma (HCC), SIK1 markedly inhibited
EMT, tumor growth and metastasis and provided a potential new candidate for HCC therapy (28). Reduced expression of SIK1 was also identified to be associated with poor outcomes in gastric carcinoma (19). Furthermore, SIK1 could be the potential target for numerous miRs. In particular, miR‑203 induces proliferation, migration and invasion by targeting SIK1 in pancreatic cancer (29). In ovarian cancer, miR‑141 promotes cell growth through reversing SIK1‑suppressed proliferation and cancer stem cell‑associated traits (30). However, the phenotypic role of SIK1 in melanoma remains largely unknown. In the present study, it was identified that downregulation of SIK1, as a target of miR‑373, elevates cell migration of melanoma.

In summary, the present study identified that miR‑373 functions as an oncomiR to promote melanoma progression through targeting SIK1 expression. This signaling pathway may provide a new therapeutic approach for melanoma.

Acknowledgements
Not applicable.

Funding
No funding was received.

Availability of data and materials
Not applicable.

Authors' contributions
XB performed the total experiments and was a major contributor in writing the manuscript. MY collected and analyzed the clinical data regarding the melanoma. YX contributed to the design of this project. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The use of human tissues was approved by the Ethics Committee of the Central Hospital of Wuhan and all patients provided written, informed consent.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
16. Lee J, Tong T, Takemori H and Jefcoate C: Stimulation of StAR expression by cAMP is controlled by inhibition of highly inducible SIK1 via CRTC2, a co-activator of CREB. Mol Cell Endocrinol 408: 80-89, 2015.